Slide 1: Second Quarter 2023 Earnings
Second Quarter 2023 Earnings August 1, 2023
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Delivered solid 2Q Non- Launched novel “Pin- COVID organic growth and Point” base editing Global launch of the adjusted EPS at the upper- platform and technology company as Revvity, Inc. end of expectations. by signing initial license Stock ticker
Slide 4: Q2'23 Revenue Highlights
Q223 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -LSD +HSD +HSD $0.7 B +LSD +LSD $0.7 B $0.7 B +HSD +DD 4 Revenue performance provided on a non-COVID organic basis Reconciliations to the most directly comparable GAAP measure f
Slide 5: 2Q23 Financial Results
2Q23 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS NON-GAAP FREE CASH FLOW $709M 28.8% $1.21 $(61)M -21% y/y -1,080bps y/y -39% y/y -179% y/y Includes $127M of AES Organic: Adj. Gross Margin: Adj. Tax Rate: related outflows -20% | M&A: 0% | FX: 0% 62.4% | -530bps y/y 22.6% Non-C
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE +3% Organic Growth 38.0% -MSD -200bps y/y Reported: 3% | M&A: 0% | FX: 0% $336 M • -LSD growth from Pharma/Biotech, +DD growth from 2Q23 revenue Academic/Gov’t +DD -DD • +DD reagents organic growth + DD - HSD • Software i
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS -34% Organic Growth 22.9% Reported: -34% | M&A: 0% | FX: -1% -2,012 bps y/y -LSD Non-COVID Organic Growth: 8% +DD $373 M 2Q23 revenue • +DD ImmunoDx ex. China, China ImmunoDx >+30% -MSD • +LSD Non-COVID o
Slide 8: 2023 Financial Guidance
2023 Financial Guidance ADJ. REVENUE $2.80B - 2.85B -15% to –14% reported Organic: -15% to -14% Non-COVID Organic: +4% to +6% FX: 0%, M&A: 0% ADJUSTED OP. MARGIN ~29% ADJUSTED EPS $4.70 - $4.90 Adj. Net interest expense, other: $63M Adjusted tax rate: 21% Average diluted share count: 125.0M 8
Slide 9: Revvity.com
Revvity.com